Shares of Connect Biopharma Holdings Limited (NASDAQ:CNTB) climbed about 11% after the company released positive findings from several clinical studies evaluating rademikibart, its anti-interleukin-4-receptor alpha antibody.
The company reported preliminary results from a Phase 1 clinical pharmacology trial showing that a single 300 mg intravenous dose of rademikibart, delivered via a two-minute IV push, produced rapid improvements in lung function among patients with asthma and chronic obstructive pulmonary disease. Many participants recorded FEV1 improvements of at least 200 mL within 15 minutes of dosing, while average FEV1 gains of roughly 200–400 mL were sustained through Day 29.
Connect Biopharma also disclosed findings from a Phase 3 study lasting 52 weeks in patients with moderate-to-severe atopic dermatitis. The RADIANT-AD trial, conducted in China by partner Simcere Pharmaceutical, showed that 96.6% of patients reached EASI-75, 87.1% achieved IGA 0/1, and 85.3% achieved EASI-90 at Week 52. The treatment was well tolerated, with a safety profile comparable to placebo.
The company said it plans to release topline results in mid-2026 from two ongoing Phase 2 Seabreeze STAT trials assessing rademikibart for acute exacerbations in asthma and COPD.
Separately, Connect Biopharma announced a private placement involving 6,130,000 ordinary shares priced at $3.25 each. The transaction is expected to generate gross proceeds of about $20.2 million before fees and expenses. The offering was led by Panacea Venture, the company’s largest existing shareholder, and is anticipated to close on or around March 31, 2026.